|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
- Richard Gonzalez CHM
- Michael Severino PRE
- Robert Michael VCH (51)
- Laura Schumacher VMG (57)
- Timothy Richmond CHO
- Henry Gosebruch EVP (48)
- Azita Saleki - Gerhardt EVP (57)
- Thomas Hudson SVP (59)
- Elaine Sorg SVP (54)
- Jeffrey Stewart SVP (52)
- Carrie Strom SVP (43)
- Brian Durkin VPR (60)
- Glenn Tilton LED (72)
- Robert Alpern IND (70)
- Roxanne Austin IND (60)
- William Burnside IND (69)
- Thomas Freyman IND (66)
- Brett Hart IND (51)
- Edward Liddy IND (75)
- Melody Meyer IND (63)
- Edward Rapp IND (63)
- Rebecca Roberts IND (68)
- Frederick Waddell IND (67)
Latest News for ABBV
Upcoming Events for ABBV
Dividend For ABBV.NLB - 0.2185 CAD
Dividend For ABBV.BA - 0.1480 USD
Dividend For ABBV34.SA - 0.4944 BRL
Dividend For ABBV.N - 1.4800 USD
Q4 2022 Abbvie Inc Earnings Release
Q1 2023 Abbvie Inc Earnings Release
AbbVie Inc Annual Shareholders Meeting
As of Today at 18:00 UTC, shares in Abbvie are trading at $163.72. This share price information is delayed by 15 minutes.
Shares in Abbvie last closed at $163.72 and the price had moved by +34.92% over the past 365 days. In terms of relative price strength the Abbvie share price has outperformed the S&P500 Index by +60.43% over the past year.
The overall consensus recommendation for Abbvie is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Abbvie dividend yield is 3.38% based on the trailing twelve month period.
Last year, Abbvie paid a total dividend of $5.53, and it currently has a trailing dividend yield of 3.38%.Looking ahead, shares in Abbvie are due to go ex-dividend on 2023-01-12 and the next dividend pay date is 2023-02-15.
Abbvie are due to go ex-dividend on 2023-01-12 and the next dividend pay date is 2023-02-15. The historic dividend yield on Abbvie shares is currently 3.38%.
To buy shares in Abbvie you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $163.72, shares in Abbvie had a market capitalisation of $289.54bn.
Here are the trading details for Abbvie:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ABBV
Based on an overall assessment of its quality, value and momentum Abbvie is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abbvie is $159.83. That is 2.38% below the last closing price of $163.72.
Analysts covering Abbvie currently have a consensus Earnings Per Share (EPS) forecast of $13.87 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbvie. Over the past six months, its share price has outperformed the S&P500 Index by +11.42%.
As of the last closing price of $163.72, shares in Abbvie were trading +9.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbvie PE ratio based on its reported earnings over the past 12 months is 13.92. The shares last closed at $163.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbvie's management team is headed by:
- Richard Gonzalez - CHM
- Michael Severino - PRE
- Robert Michael - VCH
- Laura Schumacher - VMG
- Timothy Richmond - CHO
- Henry Gosebruch - EVP
- Azita Saleki - Gerhardt - EVP
- Thomas Hudson - SVP
- Elaine Sorg - SVP
- Jeffrey Stewart - SVP
- Carrie Strom - SVP
- Brian Durkin - VPR
- Glenn Tilton - LED
- Robert Alpern - IND
- Roxanne Austin - IND
- William Burnside - IND
- Thomas Freyman - IND
- Brett Hart - IND
- Edward Liddy - IND
- Melody Meyer - IND
- Edward Rapp - IND
- Rebecca Roberts - IND
- Frederick Waddell - IND